2024-11-15T09:30:12-06:00 2023-12-31 910189318 MOSS ADAMS LLP 4747 EXECUTIVE DR SUITE 1300 SAN DIEGO CA 92121 990 2023-01-01 861024333 THE INTERNATIONAL GENOMICS CONSORTIUM INTE 6028507000 445 NORTH FIFTH STREET NO 300 PHOENIX AZ 85004 VANESA ROMERO CFO 6028507000 2024-11-14 1 0 PATRICIA J MAYER P00188643 8586271400 2023 2024-10-15 13:58:12Z DAVID MALLERY 445 NORTH FIFTH STREET NO 300 PHOENIX AZ 85004 1490033 0 X WWW.INTGEN.ORG X 2001 AZ WORK TO REVOLUTIONIZE THE TREATMENT AND PREVENTION OF CANCER AND COMPLEX DISEASES. 2 1 3 1 0 0 0 0 161 761 6 29 294023 83112 294190 83902 0 0 0 0 605795 910822 0 0 0 910746 502349 1516541 1413171 -1222351 -1329269 10251570 10812620 257915 612192 9993655 10200428 X THE MISSION OF IGC IS TO REVOLUTIONIZE THE TREATMENT AND PREVENTION OF CANCER AND COMPLEX DISEASES BY RIGOROUSLY DEVELOPING AND APPLYING POST-GENOME SCIENCE TO ADVANCES IN HUMAN HEALTH. 0 0 671685 294 ISPECIMEN - ISPECIMEN ADDRESSES A CRITICAL CHALLENGE CONNECTING LIFE SCIENCE RESEARCHERS WHO NEED HUMAN BIOSPECIMENS WITH THE BILLIONS OF SPECIMENS AVAILABLE IN HEALTHCARE ORGANIZATIONS WORLDWIDE. ISPECIMEN'S GROUND-BREAKING MARKETPLACE SOLVES THIS PROBLEM, REINVENTING THE BIOSPECIMEN PROCUREMENT PROCESS TO ACCELERATE MEDICAL RECOVERY.IGC CONTINUES TO BUILD ON THEIR ONGOING RESEARCH COLLABORATIONS WITH A VARIETY OF HOSPITALS INCLUDING WITH SCOTTSDALE HEALTHCARE HOSPITAL (NOW HONORHEALTH) BY PROVIDING ACCESS TO ITS BANKED SPECIMENS WITH CLINICAL DATA GATHERED IN COLLABORATION WITH THE HEALTH CARE CENTERS WHICH ARE REDISTRIBUTED TO SUPPORT A VARIETY OF RESEARCH INCLUDING THE CANCER GENOME ATLAS PROJECT AT THE NATIONAL CANCER INSTITUTE AND FOLLOW ON STUDIES AND DATA ACCESS QUERIES. ADDITIONALLY, IGC LEVERAGES THE SPECIMENS AND DATA COLLECTED FROM THEIR HOSPITAL AND CLINICAL COLLABORATORS TO ACCELERATE AND INCUBATE INNOVATIVE RESEARCH PROGRAMS IN WOMEN'S HEALTH, EARLY CANCER DIAGNOSTICS AND TO FIND NEW PATHWAYS FOR INNOVATIVE TREATMENT METHODS.PARADIGM DIAGNOSTICS - PARADIGM'S RESEARCH BRINGS CUTTING EDGE DIAGNOSTICS AND BIOMARKER DRIVEN CLINICAL TRIALS TO THE BENEFIT OF CANCER PATIENTS. PARADIGM ATTEMPTS TO DEVELOP POTENTIAL THERAPIES BASED ON SPECIFIC CHARACTERIZATION OF THE PATIENT'S TUMOR, PERSONALIZING EACH PATIENT'S COURSE OF TREATMENT. 1484 259 VIOMICS - DIAGNOSTIC AND BIOMARKER RESEARCH WITH A FOCUS ON LUNG CANCER. 1192 208 TISSUE FOR RESEARCH:TISSUE FOR RESEARCH WORKS WITH EXPERIENCED HIGH QUALITY FACILITIES, MOST OF WHICH ARE LOCATED IN THE U.S., IN ORDER TO ACCESS A DIVERSE RANGE OF HUMAN BIOSAMPLE TYPES, WITH THE POTENTIAL TO ORGANIZE PROSPECTIVE COLLECTIONS, WHERE EXISTING BIOREPOSITORIES DO NOT HOLD THE SAMPLES REQUIRED. TISSUE FOR RESEARCH WANTS TO MAXIMIZE THE QUALITY AND UTILITY OF THE SPECIMENS RECEIVED BY ITS CLIENTS, SO THEIR RESEARCH AND DEVELOPMENT EFFORTS SUCCEED IN IMPROVING HUMAN HEALTH.CANCER RESEARCH AND BIOSTATISTICS (CRAB):CRAB PROVIDES AN EFFICIENT AND SEAMLESS SUITE OF CLINICAL TRIAL SERVICES THAT SUPPORT INCEPTION OF THE STUDY OF PUBLICATION OF THE TRIAL RESULTS.DIAGNOSTICS ONCOLOGY CRO, LLC (DXOCRO):DXCRO IS THE LEADING CONTRACT RESEARCH ORGANIZATION (CRO) SPECIALIZINGIN THE COMMERCIALIZATION OF DIAGNOSTIC BIOMARKER TECHNOLOGIES. 1192 208 674361 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 1 1 0 0 0 1 7 0 1 3 1 0 0 0 0 0 0 0 0 0 0 0 0 X 2 1 0 0 0 0 1 0 1 1 0 0 0 1 1 1 1 1 1 1 1 0 X VANESA ROMERO 6023630174 445 NORTH FIFTH STREET NO 300 PHOENIX AZ 85004 DAVID MALLERY CEO 32.00 X X 600000 0 63981 TROY SHELTON BOARD MEMBER 0.50 X 3000 0 0 SCOTT MORRIS CSO 24.00 X 141158 0 36451 VANESA ROMERO CFO 16.00 X 40404 0 30405 784562 0 130837 2 0 1 0 0 PROGRAM REVENUE 900099 761 761 761 29 29 1489243 1406131 83112 83112 83112 83902 761 0 83141 733535 342917 390618 177287 82882 94405 98243 98243 15850 15850 10012 2500 7512 46760 46760 156237 117178 39059 7198 7198 1917 1917 4034 4034 RESEARCH & DEVELOPMENT 107624 107624 DUES & SUBSCRIPTIONS 19343 19343 TAX EXPENSES 2318 2318 32813 32813 1413171 674361 738810 0 292163 426219 756656 327208 400000 203560 753690 35794 0 140920 16009 105134 124911 8081417 8780592 776846 0 10251570 10812620 257915 612192 257915 612192 X 9993655 10200428 9993655 10200428 10251570 10812620 -1329269 1536042 0 X 0 0 0 X 1000000 1000000 1000000 3000000 1000000 1000000 1000000 3000000 3000000 1319776 1292837 1455355 1589250 1489272 7146490 10146490 8038 0.29570 0.36600 X PART I: THE ORGANIZATION IS CLASSIFIED BY THE IRS AS A 509(A)(1) ORGANIZATION. SCHEDULE A, PART II IS COMPLETED. THE ORGANIZATION CONDUCTS MEDICAL RESEARCH IN CONJUCTION WITH SCOTTSDALE HEALTHCARE HOSPITAL, SCOTTSDALE, AZ. 127340 14229 113111 13580 1780 11800 124911 X X 0 0 0 0 0 0 0 0 0 DAVID MALLERY CEO 600000 0 0 0 0 0 36000 0 27981 0 663981 0 0 0 SCOTT MORRIS CSO 141158 0 0 0 0 0 8470 0 27981 0 177609 0 0 0 CIRRUS BIO INC 35% CONTROLLED ENTITY RESEARCH X 400000 400000 0 1 1 400000 FORM 990, PART VI, SECTION A, LINE 6 THE ORGANIZATION HAS MEMBERS AS DETERMINED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7B THE MEMBERS MAY VOTE ON ANY PROPOSAL THAT WOULD REMOVE ALL MEMBERS OF THE ORGANIZATION. FORM 990, PART VI, SECTION A, LINE 8B THERE ARE NO COMMITTEES THAT HAVE AUTHORITY TO ACT ON BEHALF OF THE GOVERNING BODY. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS INITIALLY REVIEWED BY THE CFO, THEN A DRAFT IS PRESENTED TO THE BOARD FOR REVIEW/COMMENT PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION'S CONFLICT OF INTEREST POLICY APPLIES TO EACH OFFICER, DIRECTOR, TRUSTEE, KEY EMPLOYEE, HIGHEST COMPENSATED EMPLOYEE AND MEMBER OF A COMMITTEE. EACH COVERED PERSON MUST ANNUALLY COMPLETE AND PROVIDE TO THE ORGANIZATION A QUESTIONNAIRE TO IDENTIFY POTENTIAL CONFLICTS OF INTEREST. AT THE AUTHORIZED BODY'S DISCRETION, THE INTERESTED PERSON WHO IS A PARTY TO THE PROPOSED TRANSACTION OR ARRANGEMENT MAY MAKE A PRESENTATION AT THE AUTHORIZED BODY'S MEETING. IN ANY EVENT, SUCH INTERESTED PERSON AND ANY INELIGIBLE VOTERS SHALL LEAVE THE MEETING BEFORE THE DISCUSSION OF, AND VOTE ON, THE PROPOSED TRANSACTION OR ARRANGEMENT. THE NON-CONFLICTED MEMBERS SHALL, IF APPROPRIATE, APPOINT ONE OR MORE NON-CONFLICTED MEMBERS TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. SUCH INVESTIGATION MAY BE CONDUCTED DIRECTLY OR THROUGH THE USE OF OTHERS, NONE OF WHOM WOULD BE DEEMED AN INELIGIBLE VOTER IF ANY SUCH PERSON WERE A MEMBER OF THE AUTHORIZED BODY. THE NON-CONFLICTED MEMBERS SHALL DETERMINE, IN THEIR REASONABLE JUDGMENT, WHETHER THE ORGANIZATION COULD OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT FROM A PERSON THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. THE MINUTES OF THE AUTHORIZED BODY'S MEETINGS SHALL CONTAIN ALL PERTINENT DETAILS RELATED TO THE TRANSACTION OR ARRANGEMENT. FORM 990, PART VI, SECTION B, LINE 15 THE SALARIES OF THE CEO, CSO, AND CFO WERE DETERMINED USING COMPARABILITY DATA, INCLUDED A REVIEW AND APPROVAL BY INDEPENDENT BOARD MEMBERS WITH CONTEMPORANEOUS SUBSTANTIATION OF THE DELIBERATION AND DECISIONS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST. IGC MANAGEMENT SERVICES LLC 445 NORTH FIFTH STREET SUITE 300 PHOENIX AZ 85004 800361103 INVESTMENT IN IGC MGMT CORPORATION AZ 0 0 THE INTERNATIONAL GENOMICS CONSORTIUM IGC MANAGEMENT CORPORATION 445 NORTH FIFTH STREET SUITE 300 PHOENIX AZ 85004 453017176 BIOBANKING AZ IGC MANAGEMENT SERVICES LLC C 1.00000 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0